{"id":3183,"date":"2015-12-08T17:08:19","date_gmt":"2015-12-08T17:08:19","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=4860"},"modified":"2015-12-08T17:08:19","modified_gmt":"2015-12-08T17:08:19","slug":"chronic-pain-third-indication-approved-by-brazilian-government-for-medical-marijuana-inc-s-real-scientific-hemp-oil-rsho","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2015\/12\/08\/chronic-pain-third-indication-approved-by-brazilian-government-for-medical-marijuana-inc-s-real-scientific-hemp-oil-rsho\/","title":{"rendered":"Chronic Pain: Third Indication Approved by Brazilian Government for Medical Marijuana Inc.\u2019s Real Scientific Hemp Oil\u2122 (RSHO\u2122)"},"content":{"rendered":"

MJNA\u2019s Hemp Cannabidiol (CBD) Oil Products Are Shipping to Residents of Brazil With Proper
\nImportation Documentation<\/h2>\n

San Diego, Calif. — December 8, 2015 — Medical Marijuana, Inc.<\/a> (OTC Pink: MJNA) is pleased to announce to the public and its shareholders that the government of Brazil has approved chronic pain as a third indication for import of the Company\u2019s cannabidiol (CBD) hemp oil product Real Scientific Hemp Oil\u2122 (RSHO\u2122). As seen on ABC 7 News<\/a>, the first two indications to be approved for the import of RSHO\u2122 <\/a>by the Brazilian government are epilepsy<\/a> and Parkinson\u2019s disease<\/a>.<\/p>\n

The U.S. Department of Health and Human Service\u2019s patent number 6630507<\/a> states, \u201cCannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory<\/strong> and autoimmune diseases.\u201d<\/p>\n

The patent<\/a> also states, \u201cNonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.\u201d<\/p>\n

A recent market survey<\/a> report indicates that the global pain management market is projected to reach $60 billion (USD) this year. The National Institutes of Health website states, \u201cAcute pain<\/a> starts quickly and lasts less than 6 weeks. The site continues, \u201cChronic pain lasts for more than 3 months and is much less common than acute pain.\u201d<\/p>\n

Facts about chronic pain:<\/p>\n